The Latest Cardiac and Vascular News
DUBLIN – May 16, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, […]
DUBLIN – May 15, 2018 – Medtronic plc (NYSE: MDT) announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated with improved patient survival. The data were recently presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions in Boston. In a real-world, prospective registry of 1,835 patients, use […]
DUBLIN and BOSTON – May 9, 2018 – Medtronic plc (NYSE: MDT) today announced that results through 12-months from the Post-Approval Registry (PAR) for the Medtronic Micra(TM) Transcatheter Pacing System (TPS), reinforcing the high implant success rate and low complication rate seen since its U.S. approval two years ago, will be […]
DUBLIN and SAN DIEGO – April 26, 2018 – Medtronic plc (NYSE: MDT) today announced two-year outcomes for the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study. Presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, data from 18 patients followed out to two […]
BROOMFIELD, Colo.–(BUSINESS WIRE)–ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc. (NYSE:MDT), a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA’s proposed […]
DUBLIN – April 23, 2018 – Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm in patients with peripheral artery disease (PAD). Approval was based […]
DUBLIN – April 17, 2018 – Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.1 Hypervascular tumors can present as […]
DUBLIN – April 5, 2018 – Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced Laura Mauri, M.D., M.Sc., interventional cardiologist and clinical researcher at the Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, will join Medtronic as Vice President, Global Clinical Research & […]
DUBLIN – April 9, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended […]
Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO – March 10, 2018 – Medtronic plc (NYSE: MDT) today unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic […]
